Les chambres de leucoréduction sont une nouvelle source de cellules pour la génération de lignées de lymphocytes T en immunothérapie
Opportunistic reactivation of latent viruses are a significant cause of morbidity and mortality in immunocompromised patients. The transfer of ex vivo expanded pathogen T-cell lines is an attractive safe and effective strategy to treat virus related complications. The source of T cells can be either from peripheral blood or leukapheresis products of healthy donors. We evaluated the potential of PBMC from leukoreduction system chambers (LRSC) to generate therapeutic T cell products. Blood agencies usually discard LRSC that are used to leukodeplete plateletpheresis blood products which may be used as a source of T cells for manufacturing clinical scale T-cell products. The LRSCs reflect the composition of the peripheral blood except for a transient downregulation of CD62L expression in freshly extracted PBMCs from LRSCs. Non-specific stimulation revealed that LRSC or blood T cells were equivalent in terms of expansion, differentiation and function. Pathogen-specific T-cell lines from memory repertoires harvested from LRSCs and peripheral blood have equivalent proliferation, phenotype and reactivity. Moreover, PBMCs from LRSC can be used to prime and expand virus-specific T cells from seronegative donors. The large number of cells contained in LRSC and the possibility to use serial LRSC from regular platelet donors allows to create a T-cell bank ready to use.
LRSC Adoptive immunotherapy Viral reactivation Cell therapy Naïve repertoire Memory repertoire